$7.9 -0.1 -1.3%
Last Trade - 01/03/21
| Market Cap | ÂŁ195.3m |
| Enterprise Value | ÂŁ194.6m |
| Revenue | ÂŁ4.52m |
| Position in Universe | 4144th / 6633 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 2.13 | 5.64 | +164.2% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Longeveron LLC is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer’s disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.) for Aging Frailty.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| No. of Shareholders: | n/a |
| No. of Employees: | 12 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 34,409,745 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1951 NW 7th Ave Ste 520, MIAMI, 33136-1121, United States |
| Web | https://www.longeveron.com/ |
| Phone | +1 305 3027158 |
| Contact | () |
| Auditors | MSL, P.A |
As of 01/03/21, shares in Longeveron Inc are trading at $7.9, giving the company a market capitalisation of ÂŁ195.3m. This share price information is delayed by 15 minutes.
Shares in Longeveron Inc are currently trading at $7.9 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Longeveron Inc price has moved by % over the past year.
There are no analysts currently covering Longeveron Inc.
Longeveron Inc is scheduled to issue upcoming financial results on the following dates:
Longeveron Inc does not currently pay a dividend.
Longeveron Inc does not currently pay a dividend.
Longeveron Inc does not currently pay a dividend.
To buy shares in Longeveron Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Longeveron Inc are currently trading at $7.9, giving the company a market capitalisation of ÂŁ195.3m.
Here are the trading details for Longeveron Inc:
Based on an overall assessment of its quality, value and momentum, Longeveron Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Longeveron Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Longeveron Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $7.9, shares in Longeveron Inc are trading at 10.04% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Longeveron Inc.
We were unable to find the directors for Longeveron Inc.
Here are the top five shareholders of Longeveron Inc based on the size of their shareholding:
